| Ytd | 3.23% | |
| 1y | 31.87% |
| Open | 4.90 | Prev Close | 4.66 | Low | 4.80 | High | 4.93 | Mkt Cap | 249.51M |
| Vol | 568.90K | Avg Vol | 1.01M | EPS | -2.96 | P/E | -1.62 | Forward P/E | -5.16 |
| Beta | 0.89 | Short Ratio | 1.73 | Inst. Own | 25.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-30 | 50-d Avg | 4.23 | 200-d Avg | 5.06 | 1yr Est | 15.13 |
IVA News
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR
Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Date
Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris an
ADAR1 Capital Management LLC decreased its holdings in shares of Inventiva S.A. Sponsored ADR (NASDA
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and
US stock futures lower with Dow down 500 points. Kura Sushi shares drop after reporting worse-than-e
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris an
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have e
Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopha
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financ
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris an
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris an
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and
Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and
Daix (France), New York City (New York, United States), le 2 juin 2026 - Inventiva (Euronext Paris e
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (
Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its s
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu
Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy
Gainers HighPoint Resources Corporation (NYSE: HPR) shares jumped 118.8% to close at $10.83 on We